奥马珠单抗治疗顽固性慢性自发性荨麻疹疗效观察

IF 0.3 Q4 ALLERGY Astim Allerji Immunoloji Pub Date : 2018-06-18 DOI:10.21911/AAI.413
Duru Tabanlıoğlu-Onan, Ayşe Öktem, B. Yalçın, F. Artüz
{"title":"奥马珠单抗治疗顽固性慢性自发性荨麻疹疗效观察","authors":"Duru Tabanlıoğlu-Onan, Ayşe Öktem, B. Yalçın, F. Artüz","doi":"10.21911/AAI.413","DOIUrl":null,"url":null,"abstract":"Objective: Chronic spontaneous urticaria is a disorder characterized by spontaneous development of pruritic erythematous plaques, angioedema or both. Omalizumab is a recombinant monoclonal antibody that selectively binds to IgE and inhibits its binding to FceRI receptors on mast cells and basophils. We sought to retrospectively assess the efficacy of Omalizumab, the adverse effects due to treatment, and the disease-free duration after treatment in treatment-resistant chronic spontaneous urticaria cases. Materials and Methods: The treatment responses of 24 chronic spontaneous urticaria cases treated with Omalizumab at our clinic were retrospectively evaluated. Results: The mean age of the patients was 44 years and the mean duration of disease was 7.2 years. The most common concomitant systemic disease was thyroid disease (29%). The duration of treatment ranged from 4 to 36 months, and total treatment doses from 5 to 28 doses. The treatment of 15 patients was still going on and the mean duration of treatment was 24.4 months. Disease control could not be achieved in three patients but the mean dose of disease control was 3.2 in the other patients. The treatment response was partial in 29% (n=7) and complete in 71% (n=17) of the patients. Side effects (erythema or urticarial plaque at the injection area, headache, dizziness, myalgia, arthralgia) were detected in eight patients. No recurrence was detected in five patients with a mean follow-up duration of 12 months after the treatment. The mean duration until recurrence was 7.7 months after the treatment in five patients who had recurrence. Conclusion: Omalizumab is a good treatment option, thanks to its efficacy and safety, in chronic spontaneous urticaria patients who do not respond to H1-antihistamines.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2018-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria\",\"authors\":\"Duru Tabanlıoğlu-Onan, Ayşe Öktem, B. Yalçın, F. Artüz\",\"doi\":\"10.21911/AAI.413\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Chronic spontaneous urticaria is a disorder characterized by spontaneous development of pruritic erythematous plaques, angioedema or both. Omalizumab is a recombinant monoclonal antibody that selectively binds to IgE and inhibits its binding to FceRI receptors on mast cells and basophils. We sought to retrospectively assess the efficacy of Omalizumab, the adverse effects due to treatment, and the disease-free duration after treatment in treatment-resistant chronic spontaneous urticaria cases. Materials and Methods: The treatment responses of 24 chronic spontaneous urticaria cases treated with Omalizumab at our clinic were retrospectively evaluated. Results: The mean age of the patients was 44 years and the mean duration of disease was 7.2 years. The most common concomitant systemic disease was thyroid disease (29%). The duration of treatment ranged from 4 to 36 months, and total treatment doses from 5 to 28 doses. The treatment of 15 patients was still going on and the mean duration of treatment was 24.4 months. Disease control could not be achieved in three patients but the mean dose of disease control was 3.2 in the other patients. The treatment response was partial in 29% (n=7) and complete in 71% (n=17) of the patients. Side effects (erythema or urticarial plaque at the injection area, headache, dizziness, myalgia, arthralgia) were detected in eight patients. No recurrence was detected in five patients with a mean follow-up duration of 12 months after the treatment. The mean duration until recurrence was 7.7 months after the treatment in five patients who had recurrence. Conclusion: Omalizumab is a good treatment option, thanks to its efficacy and safety, in chronic spontaneous urticaria patients who do not respond to H1-antihistamines.\",\"PeriodicalId\":42004,\"journal\":{\"name\":\"Astim Allerji Immunoloji\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2018-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Astim Allerji Immunoloji\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21911/AAI.413\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Astim Allerji Immunoloji","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21911/AAI.413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:慢性自发性荨麻疹是一种以瘙痒性红斑斑块、血管性水肿或两者兼而有之为特征的疾病。Omalizumab是一种重组单克隆抗体,可选择性结合IgE并抑制其与肥大细胞和嗜碱性细胞上的FceRI受体的结合。我们试图回顾性评估治疗抵抗性慢性自发性荨麻疹病例中Omalizumab的疗效、治疗引起的不良反应以及治疗后的无病持续时间。材料与方法:回顾性评价我院24例慢性自发性荨麻疹患者使用奥玛单抗治疗的疗效。结果:患者平均年龄44岁,平均病程7.2年。最常见的全身性疾病是甲状腺疾病(29%)。治疗持续时间为4至36个月,总治疗剂量为5至28剂。15例患者仍在治疗中,平均治疗时间为24.4个月。3例患者未达到疾病控制,其余患者平均疾病控制剂量为3.2。29% (n=7)的患者有部分缓解,71% (n=17)的患者有完全缓解。8例患者出现不良反应(注射区红斑或荨麻疹斑块、头痛、头晕、肌痛、关节痛)。5例患者治疗后平均随访时间为12个月,无复发。5例复发患者治疗后至复发的平均时间为7.7个月。结论:对于h1 -抗组胺药无效的慢性自发性荨麻疹患者,Omalizumab具有良好的疗效和安全性,是一个很好的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria
Objective: Chronic spontaneous urticaria is a disorder characterized by spontaneous development of pruritic erythematous plaques, angioedema or both. Omalizumab is a recombinant monoclonal antibody that selectively binds to IgE and inhibits its binding to FceRI receptors on mast cells and basophils. We sought to retrospectively assess the efficacy of Omalizumab, the adverse effects due to treatment, and the disease-free duration after treatment in treatment-resistant chronic spontaneous urticaria cases. Materials and Methods: The treatment responses of 24 chronic spontaneous urticaria cases treated with Omalizumab at our clinic were retrospectively evaluated. Results: The mean age of the patients was 44 years and the mean duration of disease was 7.2 years. The most common concomitant systemic disease was thyroid disease (29%). The duration of treatment ranged from 4 to 36 months, and total treatment doses from 5 to 28 doses. The treatment of 15 patients was still going on and the mean duration of treatment was 24.4 months. Disease control could not be achieved in three patients but the mean dose of disease control was 3.2 in the other patients. The treatment response was partial in 29% (n=7) and complete in 71% (n=17) of the patients. Side effects (erythema or urticarial plaque at the injection area, headache, dizziness, myalgia, arthralgia) were detected in eight patients. No recurrence was detected in five patients with a mean follow-up duration of 12 months after the treatment. The mean duration until recurrence was 7.7 months after the treatment in five patients who had recurrence. Conclusion: Omalizumab is a good treatment option, thanks to its efficacy and safety, in chronic spontaneous urticaria patients who do not respond to H1-antihistamines.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
10
期刊介绍: Asthma Allergy Immunology has been published three times a year in April, August and December as the official and periodical journal of the Turkish National Society of Allergy and Clinical Immunology since 2003. All articles published in the journal have been available online since 2003. A peer reviewed system is used in evaluation of the manuscripts submitted to Asthma Allergy Immunology. The official language of the journal is English. The aim of the journal is to present advances in the field of allergic diseases and clinical immunology to the readers. In accordance with this goal, manuscripts in the format of original research, review, case report, articles about clinical and practical applications and editorials, short report and letters to the editor about allergic diseases and clinical immunology are published in the journal. The target reader population of the Asthma Allergy Immunology includes specialists and residents of allergy and clinical immunology, pulmonology, internal medicine, pediatrics, dermatology and otolaryngology as well as physicians working in other fields of medicine interested in allergy and immunological diseases.
期刊最新文献
Delayed Urticaria- Angioedema After mRNA Vaccine in an Adolescent Patient: Case Report A Father and Son Diagnosed with DiGeorge Syndrome DRESS Syndrome due to Carbamazepine Use in A Drug-Addicted Adolescent FROM THE EDITOR Identification of Novel Endochitinase Class I Based Allergens
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1